Tommaso Susini

Prof. Tommaso Susini

Head, Breast Unit, Gynecology Section, Department of Health Sciences, University of Florence, Florence, Italy
orcid

Research Focus & Metrics

Academic Career Length

31Years (1996-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 February 2007 in Gynecologic Oncology
Verified
Journal Article
Closed access
TSTommaso Susini
Tommaso Susini
JNJacopo Nori
Jacopo Nori
SOSimone Olivieri
Simone Olivieri
LLLorenzo Livi
Lorenzo Livi
SBSimonetta Bianchi
Simonetta Bianchi
GSGianfranco Scarselli
Gianfranco Scarselli

1 February 2005 in Gynecologic Oncology
Verified
Journal Article
Closed access
TSTommaso Susini
Tommaso Susini
GMGiambattista Massi
Giambattista Massi
GAGianni Amunni
Gianni Amunni
CCCarlo Carriero
Carlo Carriero
MMMauro Marchionni
Mauro Marchionni
GSGianfranco Scarselli
Gianfranco Scarselli

29 January 2007 in Cancer
Verified
Journal Article
Open access
PDF file
TSTommaso Susini
Tommaso Susini
GAGianni Amunni
Gianni Amunni
CMCecilia Molino
Cecilia Molino
CCCarlo Carriero
Carlo Carriero
SRStefano Rapi
Stefano Rapi
GSGianfranco Scarselli
Gianfranco Scarselli
BACKGROUND.: To improve the outcome of endometrial cancer patients, a more accurate prognostic assessment is mandatory. The aims of the study were to evaluate the role of flow cytometric DNA ploidy as an independent prognostic factor in patients with endometrial cancer and to verify if ploidy was able to distinguish patients with different prognosis into homogeneous subgroups for grade of differentiation and stage.METHODS.: In a prospective study, DNA ploidy was evaluated from fresh tumor samples in 174 endometrial cancer patients who underwent surgery as the first treatment. Ploidy, as well as classical parameters, were analyzed in relation to the length of disease‐free survival and disease‐specific survival.RESULTS.: DNA aneuploidy was found in 49 patients (28.2%). Patients with DNA‐aneuploid tumors had a significantly reduced disease‐free interval and disease‐specific survival (P < .0001). The 10‐year survival probability was 53.2% for DNA‐aneuploid patients and 91.0% for patients with DNA‐diploid tumors. By multivariate analysis DNA‐aneuploid type was the strongest independent predictor of poor outcome, followed by age and stage. Patients with DNA‐aneuploid tumor had a significantly higher risk ratio for recurrence (5.03) and death due to disease (6.50) than patients with DNA‐diploid tumors. Stratification by DNA‐ploidy within each group by grade of differentiation allowed identification of patients with significantly different outcome. In grade 2 tumors, 10‐year survival was 45.0% in aneuploid cases and 91.9% in diploid cases (P < .0001). Patients with advanced‐stage (>I) diploid tumor did significantly better than patients with stage I aneuploid tumor (P = .04).CONCLUSIONS.: The presence of DNA‐aneuploid type in endometrial cancer identifies high‐risk cases among the patients considered ‘low risk’ according to stage and grade of differentiation. Cancer 2007. © 2007 American Cancer Society.

1 February 2010 in Gynecologic Oncology
Verified
Journal Article
Closed access
TSTommaso Susini
Tommaso Susini
CBCecilia Bussani
Cecilia Bussani
GMGiulia Marini
Giulia Marini
JNJacopo Nori
Jacopo Nori
SOSimone Olivieri
Simone Olivieri
GSGianfranco Scarselli
Gianfranco Scarselli

1 April 2009 in The Breast
Verified
Journal Article
Closed access
TSTommaso Susini
Tommaso Susini
JNJacopo Nori
Jacopo Nori
SOSimone Olivieri
Simone Olivieri
CMCecilia Molino
Cecilia Molino
GMGiulia Marini
Giulia Marini
GSGianfranco Scarselli
Gianfranco Scarselli

8 June 2019 in Anticancer Research
Verified
Journal Article
Closed access
PDF file
TSTommaso Susini
Tommaso Susini
CCCarlo Carriero
Carlo Carriero
FTFranca Tani
Franca Tani
GMGiulia Mattioli
Giulia Mattioli
IRIrene Renda
Irene Renda
SBSimonetta Bianchi
Simonetta Bianchi
Background/Aim: Breast cancer treatment represents a substantial amount of health-care costs and has a negative impact on womens' psychological health. Day-Surgery managment (DS) is a favorable alternative to a classic inpatient setting. In our prospective study we evaluated DS-treatment feasibility in terms of patient satisfaction, same-day-discharge rate, surgical-reintervention rate, psychological impact and costs. Patients and Methods: We operated on 131 early breast cancer patients in DS. Surgical outcomes were evaluated. In 64 DS-treated breast cancer patients, psychological outcomes were analyzed using validated psychometric questionnaires and comparison was made with a corresponding group of women treated as inpatients. Results: The same-day-discharge rate was 95.4%. No patient required readmission. The surgical-reintervention rate was 6.2%. DS-treatment significantly reduced anxiety (p=0.05) and depression (p=0.01) and afforded cost savings of 49%. Conclusion: DS-treatment of early breast cancer was feasible, with low reintervention rate, reduced anxiety and depression, high patients' satisfaction and substantial financial savings.